PURPOSE: Here we present our experience with five @entity2333 ( @entity2333 ) @entity1 to better delineate the clinical and angiographic features as well as the treatment selection of this disease. METHODS: Between October 2008 and October 2012, five consecutive @entity1 diagnosed with @entity2333 were admitted to our department in our hospital. All the five @entity1 received magnetic resonance imaging, digital subtraction angiography, and positron emission computed tomography (PET) to definitively confirm this disease. We also collected 15 previously published instances of @entity2333 to analyze the characteristics of this rare entity. RESULTS: As to the five @entity1 , three were female and two were male, between the ages of 4 and 52 years with a mean age of 24.8  20.6 years. The PET results showed that perfusion was decreased over the affected hemispheres in all five @entity1 . As to the treatment, only one @entity1 received encephalo-duro-arterio-synangiosis (EDAS) revascularization surgery. The other four @entity1 were conservatively observed. During the follow-up period (range 3-6 years, mean 4  1.9 years), the @entity1 who underwent EDAS surgery manifested relief of clinical symptoms. In the conservative series, the symptoms in two @entity1 aggravated and suffered permanent @entity51 . CONCLUSION: @entity2333 is a rare entity. Natural history has showed this disease is not stable and may progress at a certain time point. The EDAS procedure may be a treatment for @entity2333 -related oligemia since there is currently little data and follow-up available.

XXXX : Clinical, angiographic features and literature review.

@entity2333 :: ('MESH:D001018', 'Disease') :: ['CPA', 'cerebral proliferative angiopathy'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficits']
@entity2333 :: (MESH:D001018,Disease) :: ['Cerebral proliferative angiopathy']
